Seres Therapeutics, Inc. (MCRB)

Market Cap	608.81M
Revenue (ttm)	5.11M
Net Income (ttm)	-264.71M
Shares Out	127.90M
EPS (ttm)	-2.30
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	891,021
Open	4.93
Previous Close	4.87
Day's Range	4.76 - 4.93
52-Week Range	2.50 - 9.49
Beta	2.62
Analysts	Strong Buy
Price Target	13.20 (+177.31%)
Earnings Date	May 9, 2023

About MCRB

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infecti...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 26, 2015
• Employees: 431
• Stock Exchange: NASDAQ
• Ticker Symbol: MCRB

Financial Performance

In 2022, MCRB's revenue was $7.13 million, a decrease of -95.08% compared to the previous year's $144.93 million. Losses were -$250.16 million, 281.5% more than in 2021.

Analyst Forecast

According to 5 analysts, the average rating for MCRB stock is "Strong Buy." The 12-month stock price forecast is $13.2, which is an increase of 177.31% from the latest price.

Price Target

$13.2

(177.31% upside)

Analyst Consensus: Strong Buy